Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.54 |
| ▸ | CDK4 | P11802 | 6/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.54 |
| ▸ | AURKA | O14965 | 5/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL699170 | 0.91 | CDK2 (0.50) | CDK2CDK4CCNE1AURKACAMK2D | |
| SCHEMBL7977540 | 0.89 | CDK2 (0.49) | CDK2CDK4CCNE1AURKACDK1 | |
| SCHEMBL7977600 | 0.86 | CDK2 (0.53) | CDK2CDK4CCNE1AURKACCNT1 | |
| SCHEMBL700586 | 0.84 | HDAC1 (0.61) | CDK2CDK4CCNE1 | |
| SCHEMBL7981330 | 0.84 | CDK2 (0.55) | CDK2CDK4CCNE1AURKACCNT1 | |
| SCHEMBL7977194 | 0.84 | CDK2 (0.55) | CDK2CDK4CCNE1AURKACCNT1 | |
| SCHEMBL10251986 | 0.83 | CCNT1 (0.46) | CDK2CDK4CCNE1AURKACCNT1 | |
| SCHEMBL7976842 | 0.83 | CDK2 (0.54) | CDK2CDK4CCNE1AURKACCNT1 | |
| SCHEMBL7975412 | 0.83 | CDK2 (0.54) | CDK2CDK4CCNE1AURKACCNT1 | |
| SCHEMBL7978515 | 0.82 | CDK2 (0.60) | CDK2CDK4CCNE1AURKACCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010009155-A2 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | CDK2 16/4885CDK4 15/4885CCNE1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.